Hot Features
프리미엄
ArriVent BioPharma Inc (AVBP)
NASDAQ
같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therap... ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. 더 보기
| 기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -3.1 | -12.4448012846 | 24.91 | 25.23 | 21.19 | 216055 | 22.57730729 | CS |
| 4 | -7.43 | -25.4103967168 | 29.24 | 29.57 | 21.19 | 176997 | 24.98137232 | CS |
| 12 | -5.57 | -20.3433162893 | 27.38 | 29.71 | 21.19 | 161756 | 26.09123992 | CS |
| 26 | -5.08 | -18.8917813313 | 26.89 | 36.37 | 21.19 | 214549 | 26.553792 | CS |
| 52 | 1.33 | 6.494140625 | 20.48 | 36.37 | 14.35 | 167803 | 24.22399676 | CS |
| 156 | -2.19 | -9.125 | 24 | 36.37 | 14.35 | 173790 | 23.77359626 | CS |
| 260 | -2.19 | -9.125 | 24 | 36.37 | 14.35 | 173790 | 23.77359626 | CS |
